Creative Medical Technology Holdings, Inc. (CELZ) Stock Score, Valuation & Financial Research
Creative Medical Technology Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for CELZ
Creative Medical Technology Holdings, Inc. currently has a Wall Street Score of 24/100. The stored market price is $0.94. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Creative Medical Technology Holdings, Inc. does
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
CELZ financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $0.94
- Market capitalization:
- $2.4M
- Revenue:
- $3K
- Net income:
- $-6.0M
- Free cash flow:
- $-5.9M
- Cash:
- $8.7M
- Total debt:
- $14K
- EPS:
- -2.00
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.5%.
- Free cash flow is $-5.9M, showing cash burn in the current stored period.
- The balance sheet shows $8.7M of cash versus $14K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.3 points: CELZ increased 0.3 points because Capital improved by 4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CELZ
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.